Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT04260698

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Conditions: Hematological Malignancies

Sex: All

Ages: 12 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 36

Sponsor: Gamida Cell ltd

Location: UCLA Los Angeles California

Summary

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Eligibility Criteria

Inclusion Criteria: * Patients must be at least 12 years of age * Applicable disease criteria * Patients must have one or two partially HLA-matched CBUs * Back-up stem cell source * Sufficient physiological reserves * Females of childbearing potential agree to use appropriate method of contraception * Signed written informed consent Exclusion Criteria: * Extensive bone marrow fibrosis * Donor specific anti-HLA antibodies * Pregnancy * Medically unsuitable for transplant

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04260698). StuddyBuddy aggregates publicly available trial information.